403 research outputs found

    Competing risks after coronary bypass surgeryThe influence of death on reintervention

    Get PDF
    AbstractObjective: For groups of patients at high risk of death, such as older patients, the actual probability of experiencing a nonfatal event, such as reintervention, must be far smaller than the potential probability were there no attrition by death. Competing risks analysis quantifies the difference. Methods: Multivariable analyses were performed for the competing events death before reintervention, reoperation, and percutaneous transluminal coronary angioplasty in 2001 patients after bilateral internal thoracic artery grafting and in 8123 after single internal thoracic artery grafting. Follow-up was 9.7 ± 3.0 years and 10.8 ± 5.2 years in bilateral and single internal thoracic artery groups, respectively. Results: Patients receiving single grafts experienced shorter survival and more reinterventions (P < .0001). However, other risk factors for death included old age (P < .0001), but risk factors for reintervention included young age (P < .0001). This difference confounds interpretation of event-free survival that is clarified by competing risks analysis. Death reduced the potential benefit of bilateral internal thoracic artery grafting on reintervention by angioplasty from a median of 8.5% to 5.5% at 12 years and by reoperation from 9.3% to 6.8%, with progressively greater erosion of benefit from attrition by death as age increased. Competing risks simulation confirmed that young age was a true risk factor for reintervention, excluding the explanation that it reflected simply passive attrition by death as patients age. Conclusions: Even after accounting for attrition by interim deaths, bilateral versus single internal thoracic artery grafting and older age are associated with fewer reinterventions. However, in high-risk patients, its benefit on freedom from reintervention is eroded considerably by death. (J Thorac Cardiovasc Surg 2000;119:1221-32

    Neurologic injury from cardiac surgery—an important but enormously complex phenomenon

    Get PDF
    AbstractJ Thorac Cardiovasc Surg 2003;125:S28-3

    Random survival forests

    Full text link
    We introduce random survival forests, a random forests method for the analysis of right-censored survival data. New survival splitting rules for growing survival trees are introduced, as is a new missing data algorithm for imputing missing data. A conservation-of-events principle for survival forests is introduced and used to define ensemble mortality, a simple interpretable measure of mortality that can be used as a predicted outcome. Several illustrative examples are given, including a case study of the prognostic implications of body mass for individuals with coronary artery disease. Computations for all examples were implemented using the freely available R-software package, randomSurvivalForest.Comment: Published in at http://dx.doi.org/10.1214/08-AOAS169 the Annals of Applied Statistics (http://www.imstat.org/aoas/) by the Institute of Mathematical Statistics (http://www.imstat.org

    Analysis of morbid events and risk factors for death after cardiac transplantation

    Get PDF
    AbstractRisk factors for death after cardiac transplantation performed at the University of Alabana at Birmingham from January 1981 to July 1985 included (by multivariate analysis) higher calculated preoperative pulmonary vascular resistance (early and constant phases), murphology of cardiomyopathy (versus ischemic heart disease) (constant phase only) and black race (constant phase). overall actuarial survival was 71% at 1 year and 48% at 3 years (including azalhioprine and cyclosporine eras). The hazard function for death was highest immediately after operation and declined rapidly thereafter, merging with a constant phase of risk at about 3 months.The most favorable group for long-term survival was the group of white patients with ischemic heart disease and low pulmonary vascular resistance. When such patients had a pulmonary vascular resistance < 3 units m2, the 3 year survival rate exceeded 85%; The most common causes of death were acute rejection (24%) and infection (17%) The risk of infection remained highest during the first several months after any period of augmented immunosuppression

    Fate of the esophagogastric anastomosis

    Get PDF
    ObjectiveThe study objective was to evaluate histopathology of the esophagogastric anastomosis after esophagectomy, determine time trends of histologic changes, and identify factors influencing those findings.MethodsA total of 231 patients underwent 468 upper gastrointestinal endoscopies with anastomotic biopsy a median of 3.5 years after esophagectomy. Mean age was 59 ± 12 years, 74% (171) were male, and 96% (222) were white. Seventy-eight percent (179) had esophagectomy for cancer, 13% (30) had chemoradiotherapy, and 13% (30) had prior esophageal surgery. The anastomosis was 20 ± 2.0 cm from the incisors. Anti-reflux medications were used in 59% of patients (276/468) at esophagoscopy. Histopathology was graded as normal (0), consistent with reflux (1), cardia mucosa (2), intestinal metaplasia (3), and dysplasia (4). Repeated-measures nonlinear time-trend analysis and multivariable analyses were used.ResultsGrades 0 and 1 were constant, 5% and 92% at 10 years, respectively. Anti-reflux medication, induction therapy, and higher anastomosis were predictive of less grade 1 histopathology. Grades 2 and 3 increased with time: 12% and 33% at 5 years and 4% and 16% at 10 years, respectively. No variable was predictive of grade 2 or 3 (P > .15) except passage of time. No patient’s condition progressed to dysplasia or cancer.ConclusionsThe esophagogastric anastomosis is subject to gastroesophageal reflux. To minimize histopathologic changes of reflux, the anastomosis should be constructed as high as possible (closer to incisors) and anti-reflux medications prescribed. Surveillance endoscopy, if performed, will document a time-related progression of reflux-related histopathologic changes. However, during surveillance, intestinal metaplasia is uncommon and progression to cancer rare
    • …
    corecore